Phase 2 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of HSK31858 in Participants with Non-cystic Fibrosis Bronchiectasis
Latest Information Update: 01 Oct 2024
At a glance
- Drugs HSK 31858 (Primary)
- Indications Bronchiectasis
- Focus Therapeutic Use
- Sponsors Haisco Pharmaceutical Group
- 26 Sep 2024 Status changed from recruiting to completed.
- 06 Dec 2022 Status changed from not yet recruiting to recruiting.
- 03 Nov 2022 New trial record